#Canada #CFO #Toronto #IM Cannabis #Asi Levi

IM Cannabis Appoints Asi Levi as Chief Financial Officer

In a move aimed at enhancing its financial leadership, IM Cannabis Corp. has recently appointed Asi Levi as its new Chief Financial Officer (CFO). The decision, effective immediately, follows the tenure of Uri Birenberg, who the company thanked for his contributions during his time in the role.

Asi Levi brings over 15 years of experience in finance and controlling positions to IM Cannabis, with a solid track record that includes leadership roles at Water Ways Technologies Inc. and DekelOil CI. His extensive background in finance encompasses areas such as fundraising, financial planning, budgeting, and cash flow management. Levi's expertise in compliance with international financial reporting standards (IFRS) is expected to bolster IM Cannabis's financial infrastructures and practices—especially as the company expands its operations in international markets such as Israel and Germany.

IM Cannabis is a leading player in the medical cannabis sector, focusing on providing high-quality products to patients in one of the world's most rapidly growing markets. The company's international footprint primarily extends across Israel and Germany, tapping into the vast potential of medical cannabis in these regions. The appointment of Levi comes at a crucial time as IM Cannabis seeks to achieve sustainable growth in these high-value markets.

The company has outlined a forward-looking strategy that aims to leverage a unique data-driven approach to streamline its operations and strengthen its supply chain. With an unwavering commitment to regulatory compliance and responsible growth, IM Cannabis is determined to amplify its commercial presence and solidify its status as a global cannabis leader.

IM Cannabis operates a comprehensive ecosystem in Israel, featuring subsidiaries that import and distribute cannabis products to medical patients. The company utilizes years of proprietary data and insights gained from patient experiences, facilitating a streamlined distribution process that ensures quality control and safety throughout the entire value chain.

In Germany, IM Cannabis has established operations through its subsidiary, Adjupharm GmbH, where it is engaged in distributing cannabis products to local pharmacies serving patients with medical cannabis prescriptions. This expansive ecosystem reflects the company's aim to remain at the forefront of a rapidly evolving industry and to address the increasing demand for medical cannabis in European markets.

Asai Levi’s appointment signals a strengthening of the financial leadership structure within IM Cannabis, particularly as the company prepares for growth and navigates the complexities of regulatory environments across borders. His experience is expected to prove invaluable as the company continues to develop its financial strategies amidst an ever-changing landscape in the cannabis industry.

With the growing acceptance and legalization of cannabis in various countries, IM Cannabis Corp. is well-positioned to capture market opportunities, thanks to its strategic planning and market-oriented approach. The combination of strong financial governance and operational excellence will likely propel IM Cannabis into its next phase of growth, full of potential and promise for stakeholders and patients alike.

In summary, with Asi Levi stepping into the role of CFO, IM Cannabis not only honors the contributions of its former financial leadership but also reaffirms its commitment to establishing robust financial frameworks that can adapt to future challenges and foster success in the highly competitive cannabis market.